ReviewAntibiotics (Basel, Switzerland)2020
Review on Current Status of Echinocandins Use.
Review in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 90 citations in OpenAlex.
- A phase I randomized, double-blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects.Clinical and translational science · 2022Trial
- Article
- Lipid-Based Drug Delivery Systems as Emerging Tools to Overcome Antifungal Resistance.International journal of molecular sciences · 2026Review
- Irrational and Inappropriate Use of Antifungals in the NICU: A Narrative Review.Antibiotics (Basel, Switzerland) · 2026Review
- Novel Targets and Nanotechnology Approaches in Treating Vulvovaginal Candidiasis: Insights into Host-Microbe Interactions and Immunotherapy.Current pharmaceutical design · 2026Review
- From the Ground to the Clinic: The Evolution and Adaptation of Fungi.Journal of fungi (Basel, Switzerland) · 2025Review
- A zinc-chelating cyclic alkyl polyamine compound is efficient and safe in a murine model of multidrug-resistantAntimicrobial agents and chemotherapy · 2025Article
- Pharmacological Management of Oral and Esophageal Candidiasis: A Clinical Pharmacotherapy Perspective.Journal of clinical medicine · 2025Review
- Ultrastructural and Immunohistochemical Study on the Nephrotoxicity Following Intravitreal Administration of the Antifungal Agents Voriconazole and Micafungin in New Zealand White Rabbits.International journal of molecular sciences · 2025Article
- Exploring fungal survival mechanisms: toward next-generation antifungal therapies against Candida spp.Archives of microbiology · 2025Review
- Antifungal efficacy of cinnamaldehyde and nano-cinnamaldehyde particles against candidiasis: an in-vitro study.BMC oral health · 2025Article
- Antifungal Drugs for the Treatment of Invasive Fungal Infections-A Limited Therapeutic Toolbox Facing Growing Resistances.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Article
- Candida albicans: the current status regarding vaginal infections.Applied microbiology and biotechnology · 2025Review
- Resilience in Resistance: The Role of Cell Wall Integrity in Multidrug-Resistant Candida.Journal of fungi (Basel, Switzerland) · 2025Review
- Recent innovations and challenges in the treatment of fungal infections.Frontiers in cellular and infection microbiology · 2025Review
- The evolution of antifungal therapy: Traditional agents, current challenges and future perspectives.Current research in microbial sciences · 2025Review
- Perspectives on the Use of Echinocandins in the Neonatal Intensive Care Unit.Antibiotics (Basel, Switzerland) · 2024Review
- Inhibition of Virulence Associated Traits by β-Sitosterol Isolated from Hibiscus rosa-sinensis Flowers Against Candida albicans: Mechanistic Insight and Molecular Docking Studies.Journal of microbiology (Seoul, Korea) · 2024Article
- Natural Products That Contain Higher Homologated Amino Acids.Chembiochem : a European journal of chemical biology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fungal infections are rising all over the world every year. There are only five medical compound classes for treatment: triazoles, echinocandins, polyenes, flucytosine and allylamine. Currently, echinocandins are the most important compounds, because of their wide activity spectrum and much lower sides effects that may occur during therapy with other drugs. Echinocandins are secondary metabolites of fungi, which can inhibit the biosynthesis of β-(1,3)-D-glucan. These compounds have fungicidal and fungistatic activity depending on different genera of fungi, against which they are used. Echinocandin resistance is rare-the major cause of resistance is mutations in the gene encoding the β-(1,3)-D-glucan synthase enzyme. In this review of the literature we have summarized the characteristics of echinocandins, the mechanism of their antifungal activity with pharmacokinetics and pharmacodynamics, and the resistance issue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.